These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 19398455

  • 1. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2009 Jul; 64(1):94-100. PubMed ID: 19398455
    [Abstract] [Full Text] [Related]

  • 2. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
    [Abstract] [Full Text] [Related]

  • 3. RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections.
    Cirioni O, Giacometti A, Ghiselli R, Dell'Acqua G, Orlando F, Mocchegiani F, Silvestri C, Licci A, Saba V, Scalise G, Balaban N.
    J Infect Dis; 2006 Jan 15; 193(2):180-6. PubMed ID: 16362881
    [Abstract] [Full Text] [Related]

  • 4. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
    Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2000 May 15; 41(6):1432-7. PubMed ID: 10798659
    [Abstract] [Full Text] [Related]

  • 5. [Topical use of lysostaphin for Staphylococcus aureus infection of burn wounds in mice].
    Huan JN.
    Zhonghua Wai Ke Za Zhi; 1992 May 15; 30(5):270-1, 316. PubMed ID: 1289000
    [Abstract] [Full Text] [Related]

  • 6. In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci.
    Lee JY, Ko KS, Peck KR, Oh WS, Song JH.
    J Antimicrob Chemother; 2006 Jun 15; 57(6):1110-5. PubMed ID: 16556639
    [Abstract] [Full Text] [Related]

  • 7. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP, Gemmell CG, Coote PJ.
    Int J Antimicrob Agents; 2010 Jun 15; 35(6):559-65. PubMed ID: 20206480
    [Abstract] [Full Text] [Related]

  • 8. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection.
    Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Orlando F, Mocchegiani F, Silvestri C, Licci A, Chiodi L, Lukasiak J, Saba V, Scalise G.
    Peptides; 2006 Jun 15; 27(6):1210-6. PubMed ID: 16289474
    [Abstract] [Full Text] [Related]

  • 9. Lysostaphin: an antistaphylococcal agent.
    Kumar JK.
    Appl Microbiol Biotechnol; 2008 Sep 15; 80(4):555-61. PubMed ID: 18607587
    [Abstract] [Full Text] [Related]

  • 10. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.
    Shah A, Mond J, Walsh S.
    Antimicrob Agents Chemother; 2004 Jul 15; 48(7):2704-7. PubMed ID: 15215130
    [Abstract] [Full Text] [Related]

  • 11. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland.
    Bramley AJ, Foster R.
    Res Vet Sci; 1990 Jul 15; 49(1):120-1. PubMed ID: 2382049
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis.
    Ha KR, Psaltis AJ, Butcher AR, Wormald PJ, Tan LW.
    Laryngoscope; 2008 Mar 15; 118(3):535-40. PubMed ID: 18090864
    [Abstract] [Full Text] [Related]

  • 13. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.
    Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2002 Dec 15; 43(12):3712-6. PubMed ID: 12454041
    [Abstract] [Full Text] [Related]

  • 14. Model of Staphylococcus aureus central venous catheter-associated infection in rats.
    Ulphani JS, Rupp ME.
    Lab Anim Sci; 1999 Jun 15; 49(3):283-7. PubMed ID: 10403443
    [Abstract] [Full Text] [Related]

  • 15. Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.
    Dell'Acqua G, Giacometti A, Cirioni O, Ghiselli R, Saba V, Scalise G, Gov Y, Balaban N.
    J Infect Dis; 2004 Jul 15; 190(2):318-20. PubMed ID: 15216467
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Lysostaphin functionalized silicon catheter for the prevention of Staphylococcus aureus biofilm.
    Jayakumar J, Vinod V, Arumugam T, Sathy BN, Biswas L, Kumar VA, Biswas R.
    Int J Biol Macromol; 2024 Jan 15; 256(Pt 2):128547. PubMed ID: 38048926
    [Abstract] [Full Text] [Related]

  • 17. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW, Patron RL, Goldstein BP, Archer GL.
    Antimicrob Agents Chemother; 1998 Jun 15; 42(6):1355-60. PubMed ID: 9624475
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination.
    Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S.
    J Antimicrob Chemother; 2009 Jul 15; 64(1):88-93. PubMed ID: 19447791
    [Abstract] [Full Text] [Related]

  • 19. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model.
    Yu J, Wu J, Francis KP, Purchio TF, Kadurugamuwa JL.
    J Antimicrob Chemother; 2005 Apr 15; 55(4):528-34. PubMed ID: 15743898
    [Abstract] [Full Text] [Related]

  • 20. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis.
    McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O'Callaghan RJ.
    Curr Eye Res; 2006 Mar 15; 31(3):225-30. PubMed ID: 16531279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.